Harbour BioMed
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
22 Strathmore Rd Ste 355, Natick, Massac...Phone Number
(617) 682-3679Website
www.harbourbiomed.comRevenue
$89.5 MillionStock Symbol
2142.HKIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Harbour BioMed
Harbour BioMed is a global, clinical-stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. Harbour BioMed was founded in 2016 and is headquartered in Massachusetts.Explore more
Harbour BioMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Harbour BioMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Harbour BioMed had a recent Job posting/layoffs
Earning: See what the market has to say on Harbour BioMed recently announced quarterly report
Check out if Harbour BioMed is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Harbour BioMed launches new products
Congratulate Masked Content for being promoted to Masked Content at Harbour BioMed
Funding: Get notified immidiatlly once Harbour BioMed has new funding data
Check if Harbour BioMed has recently received funding, and reach out quickly before it becomes old news!
Harbour BioMed, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Harbour BioMed
Find 3 more new buyers
Compare Similar Companies to Harbour BioMed
Compare insights from companies similar to Harbour BioMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.7B
201-500
Public
$1.1B
1998
RP
Rodney PlanchonManager, Quality Control & Chief Marketing Officer, External
Company Profile Activity
Activity Insights
Harbour BioMed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Harbour BioMed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Harbour BioMed.
Harbour BioMed financials insights
Gather financial insights about Harbour BioMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$75M
Series C
$102.8M
Harbour BioMed Tech Stack
A closer look at the technologies used by Harbour BioMed
Most Recent Scoops
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Partnership, Research & Development
Person-Based
Earnings, Forecasting, Finance
Person-Based
Earnings, Finance
Harbour BioMed News & Media
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. HBM9378/WIN378...HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. HBM9378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbatiHarbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Today, shares of Harbour BioMed (the "Company"; HKEX: 02142.HK) were officially included in the eligible shares list of the Stock Connect. Effective immediately, qualified investors in mainland China can...Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Mr. Youchen Chen, Chief Financial Officer, and Dr. Ian Y. Liu, Senior Vice President and Global Head of Legal, as Executive Directors of the Company, effective immediately. The appointm
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Harbour BioMed
Sign Up For FreeTo access detailed company insights
Harbour BioMed is a global, clinical-stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. Harbour BioMed was founded in 2016 and is headquartered in Massachusetts.... Read More
